The full text of this article

 

Estimating the cost of clinical innovation: parametric analysis of late stage pharmaceutical R&D
by Giampiero Favato, Roger W. Mills, Bill Weinstein
International Journal of Technology Intelligence and Planning (IJTIP), Vol. 3, No. 3, 2007

 

Abstract: Major pharmaceutical companies are placing significant emphasis on reducing spiralling R&D expenditures and improving productivity. Clinical trials cost estimates positively affect the quality of stop/go decision making in late stage clinical development. The major quantitative challenge has been identified as how to estimate a priori the cost of clinical trials and prior research on this subject has been based upon a limited sample of drugs in development and depends upon average cost data released by the industry. The application of parametric cost analysis to pharmaceutical development can help reduce the uncertainty and the degree of approximation of the cost estimates.

Online publication date: Wed, 14-Nov-2007

 

is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

 
Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

 
Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Intelligence and Planning (IJTIP):
Login with your Inderscience username and password:

 

    Username:        Password:         

Forgotten your password?


 
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

 
If you still need assistance, please email subs@inderscience.com